Roberto Cauda

List of Publications by Year
in descending order

220 papers	12,621 citations	28274 55 h-index	29157 104 g-index
223 all docs	223 docs citations	223 times ranked	16883 citing authors

#	Article	IF	Citations
1	The electrostatic potential of the Omicron variant spike is higher than in Delta and Deltaâ€plus variants: A hint to higher transmissibility?. Journal of Medical Virology, 2022, 94, 1277-1280.	5.0	60
2	The SARSâ€CoVâ€2 Mu variant should not be left aside: It warrants attention for its immunoâ€escaping ability. Journal of Medical Virology, 2022, 94, 2479-2486.	5.0	6
3	The value of electrostatic potentials of the spike receptor binding and N-terminal domains in addressing transmissibility and infectivity of SARS-CoV-2 variants of concern. Journal of Infection, 2022, 84, e62-e63.	3.3	17
4	People Living with HIV in the COVID-19 Era: A Case Report. AIDS Research and Human Retroviruses, 2021, 37, 253-254.	1.1	7
5	Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: The Multicenter Italian CORIST Study. Thrombosis and Haemostasis, 2021, 121, 1054-1065.	3.4	87
6	Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemaseâ€“Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study. Clinical Infectious Diseases, 2021, 73, 1664-1676.	5.8	130
7	Hydroxychloroquine and mortality in COVID-19 patients: a systematic review and a meta-analysis of observational studies and randomized controlled trials. Pathogens and Global Health, 2021, 115, 456-466.	2.3	13
8	Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering. Journal of Healthcare Engineering, 2021, 2021, 1-10.	1.9	2
9	SARSâ€CoVâ€2 B.1.617 Indian variants: Are electrostatic potential changes responsible for a higher transmission rate?. Journal of Medical Virology, 2021, 93, 6551-6556.	5.0	79
10	Risk of burnout and stress in physicians working in a COVID team: A longitudinal survey. International Journal of Clinical Practice, 2021, 75, e14755.	1.7	13
11	Shortening Epitopes to Survive: The Case of SARS-CoV-2 Lambda Variant. Biomolecules, 2021, 11, 1494.	4.0	5
12	Psychological distress during the initial stage of the COVID-19 pandemic in an Italian population living with HIV: an online survey. Infezioni in Medicina, 2021, 29, 54-64.	1.1	3
13	Sarilumab use in severe SARS-CoV-2 pneumonia. EClinicalMedicine, 2020, 27, 100553.	7.1	66
14	Assessment of neurological manifestations in hospitalized patients with COVIDâ€19. European Journal of Neurology, 2020, 27, 2322-2328.	3.3	36
15	Knowing more about chloroquine/hydroxycloroquine in COVID-19 patients. Future Microbiology, 2020, 15, 1523-1526.	2.0	3
16	COVID-19 and intestinal inflammation: Role of fecal calprotectin. Digestive and Liver Disease, 2020, 52, 1231-1233.	0.9	40
17	Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1899-1913.	2.6	137
18	Ethical Criteria for the Admission and Management of Patients in the ICU Under Conditions of Limited Medical Resources: A Shared International Proposal in View of the COVID-19 Pandemic. Frontiers in Public Health, 2020, 8, 284.	2.7	17

#	Article	IF	Citations
19	Antibiotic appropriateness and adherence to local guidelines in perioperative prophylaxis: results from an antimicrobial stewardship intervention. Antimicrobial Resistance and Infection Control, 2020, 9, 164.	4.1	20
20	Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study. European Journal of Internal Medicine, 2020, 82, 38-47.	2.2	88
21	Day 10 Post-Prescription Audit Optimizes Antibiotic Therapy in Patients with Bloodstream Infections. Antibiotics, 2020, 9, 437.	3.7	1
22	Evidence for mutations in SARSâ€CoVâ€2 Italian isolates potentially affecting virus transmission. Journal of Medical Virology, 2020, 92, 2232-2237.	5.0	28
23	A call to research: the relationship between SARS-2-CoV, ACE 2 and antihypertensives. Pathogens and Global Health, 2020, 114, 165-167.	2.3	3
24	Evolution of cellular HIV DNA levels in virologically suppressed patients switching to dolutegravir/lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study. Journal of Antimicrobial Chemotherapy, 2020, 75, 1599-1603.	3.0	10
25	Evolutionary analysis of SARS-CoV-2: how mutation of Non-Structural Protein 6 (NSP6) could affect viral autophagy. Journal of Infection, 2020, 81, e24-e27.	3.3	211
26	Offâ€label use of tocilizumab in patients with SARSâ€CoVâ€2 infection. Journal of Medical Virology, 2020, 92, 1787-1788.	5.0	102
27	Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line. International Journal of Antimicrobial Agents, 2020, 56, 106017.	2.5	97
28	RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies. Vascular Pharmacology, 2020, 135, 106805.	2.1	39
29	Liability of Health Care Professionals and Institutions During COVID-19 Pandemic in Italy: Symposium Proceedings and Position Statement. Journal of Patient Safety, 2020, 16, e299-e302.	1.7	24
30	Performance evaluation of the (1,3)-β-D-glucan detection assay in non-intensive care unit adult patients. Infection and Drug Resistance, 2019, Volume 12, 19-24.	2.7	11
31	Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused byKlebsiella pneumoniaeCarbapenemaseâ€“producingK. pneumoniae. Clinical Infectious Diseases, 2019, 68, 355-364.	5.8	265
32	Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults. Infectious Diseases and Therapy, 2019, 8, 453-462.	4.0	2
33	Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients. HIV Research and Clinical Practice, 2019, 20, 92-98.	1.1	10
34	Role of place of acquisition and inappropriate empirical antibiotic therapy on the outcome of extended-spectrum Î²-lactamase-producing Enterobacteriaceae infections. International Journal of Antimicrobial Agents, 2019, 54, 49-54.	2.5	15
35	A pilot experience of common European infectious diseases curriculum for medical students: the IDEAL summer school. Future Microbiology, 2019, 14, 369-372.	2.0	1
36	Liver fibrosis is associated with cognitive impairment in people living with HIV. Infection, 2019, 47, 589-593.	4.7	4

#	Article	IF	Citations
37	Incidence of Bloodstream Infections, Length of Hospital Stay, and Survival in Patients With RecurrentClostridioides difficileInfection Treated With Fecal Microbiota Transplantation or Antibiotics. Annals of Internal Medicine, 2019, 171, 695.	3.9	81
38	Cognitive impairment and cardiovascular disease related to alexithymia in a well-controlled HIV-infected population. Infezioni in Medicina, 2019, 27, 274-282.	1.1	3
39	3-Year Efficacy and Durability of Simplification to Single Tablet Regimens: A Comparison between Co-Formulated Efavirenz/Emtricitabine/Tenofovir and Rilpivirine/Emtricitabine/Tenofovir. Antiviral Therapy, 2018, 23, 139-148.	1.0	9
40	Systematic clinical management of patients with candidemia improves survival. Journal of Infection, 2018, 77, 145-150.	3.3	13
41	Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection. International Journal of Antimicrobial Agents, 2018, 51, 244-248.	2.5	55
42	Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy. Journal of Antimicrobial Chemotherapy, 2018, 73, 1949-1954.	3.0	17
43	Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. Journal of Antimicrobial Chemotherapy, 2018, 73, 1955-1964.	3.0	29
44	Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort). International Journal of Epidemiology, 2017, 46, dyv192.	1.9	15
45	Verbal list learning and memory profiles in HIV-infected adults, Alzheimerâ€™s disease, and Parkinsonâ€™s disease: An evaluation of the â€œcortical hypothesisâ€•of NeuroAIDS. Applied Neuropsychology Adult, 2017, 24, 410-419.	1.2	11
46	Trimethoprimâ€“sulfamethoxazole therapy for patients with carbapenemase-producing Klebsiella pneumoniae infections: retrospective single-center case series. Infection, 2017, 45, 209-213.	4.7	21
47	Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial. Journal of Antimicrobial Chemotherapy, 2017, 72, 2055-2059.	3.0	28
48	Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients. Journal of Chemotherapy, 2017, 29, 299-307.	1.5	5
49	Antibiotic stewardship from toolkit to local implementation: the â€˜gutta cavat lapidemâ€™ strategy. Future Microbiology, 2017, 12, 935-938.	2.0	3
50	Recommendations for the inclusion of Fabry disease as a rare febrile condition in existing algorithms for fever of unknown origin. Internal and Emergency Medicine, 2017, 12, 1059-1067.	2.0	7
51	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. The Lancet Gastroenterology and Hepatology, 2017, 2, 427-434.	8.1	15
52	Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients. Aids, 2017, 31, 457-459.	2.2	36
53	Antibodies against a Î²-glucan-protein complex of Candida albicans and its potential as indicator of protective immunity in candidemic patients. Scientific Reports, 2017, 7, 2722.	3.3	12
54	International infectious diseases teaching to undergraduate medical students: A successful European collaborative experience. Medical Teacher, 2017, 39, 981-986.	1.8	3

#	Article	IF	Citations
55	Treatment simplification to atazanavir/ritonavirâ€‰+â€‰lamivudine versus maintenance of atazanavir/ritonavirâ€‰+â€‰two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). Journal of Antimicrobial Chemotherapy, 2017, 72, dkw557.	3.0	62
56	Characteristics of Staphylococcus aureus Bacteraemia and Predictors of Early and Late Mortality. PLoS ONE, 2017, 12, e0170236.	2.5	67
57	Generic antiretrovirals for the treatment of HIV: a novel challenge for Western countries?. International Journal of Clinical Pharmacology and Therapeutics, 2017, 55, 381-393.	0.6	6
58	Risk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral Treatment. PLoS ONE, 2016, 11, e0162320.	2.5	16
59	A Murine, Bispecific Monoclonal Antibody Simultaneously Recognizing Î²-Glucan and MP65 Determinants in Candida Species. PLoS ONE, 2016, 11, e0148714.	2.5	11
60	Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study. PLoS ONE, 2016, 11, e0156523.	2.5	21
61	Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE). Clinical Neuropsychologist, 2016, 30, 1457-1468.	2.3	19
62	Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study. Journal of Antimicrobial Chemotherapy, 2016, 71, 3621-3622.	3.0	3
63	Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients. Journal of Infection, 2016, 73, 619-623.	3.3	11
64	Impact of antibiotic stewardship on perioperative antimicrobial prophylaxis. International Journal for Quality in Health Care, 2016, 28, 502-507.	1.8	19
65	Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection. Infectious Diseases, 2016, 48, 48-55.	2.8	5
66	Cognitive reserve and neuropsychological functioning in older HIV-infected people. Journal of NeuroVirology, 2016, 22, 575-583.	2.1	33
67	Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine. Journal of Immunoassay and Immunochemistry, 2016, 37, 189-200.	1.1	5
68	Baseline CD4⁺ T-cell Count and Cardiovascular Risk Factors Predict the Evolution of Cognitive Performance During 2-Year follow-up in HIV-Infected Patients. Antiviral Therapy, 2015, 20, 433-440.	1.0	11
69	Antiretroviral Neuropenetration Scores Better Correlate with Cognitive Performance of HIV-Infected Patients after Accounting for drug Susceptibility. Antiviral Therapy, 2015, 20, 441-447.	1.0	34
70	Resource-saving advice from an infectious diseases specialist team in a large university hospital: an exportable model?. Future Microbiology, 2015, 10, 15-20.	2.0	8
71	Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. Journal of Antimicrobial Chemotherapy, 2015, 70, 2133-2143.	3.0	434
72	Prevalence, incidence and predictors of anal high-risk HPV infections and cytological abnormalities in HIV-infected individuals. Journal of Infection, 2015, 70, 60-71.	3.3	12

#	Article	IF	Citations
73	Liver fibrosis is associated with cognitive impairment in HIVâ€positive patients. Journal of the International AIDS Society, 2014, 17, 19722.	3.0	5
74	Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study. Journal of the International AIDS Society, 2014, 17, 19816.	3.0	7
75	Safety of darunavir/ritonavir (DRV/r) in HIV-1-infected DRV/r-experienced and -naÃ¯ve patients: analysis of data in the real-world setting in Italy. Journal of the International AIDS Society, 2014, 17, 19573.	3.0	5
76	Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre. Journal of the International AIDS Society, 2014, 17, 19817.	3.0	7
77	Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study). Scandinavian Journal of Infectious Diseases, 2014, 46, 34-45.	1.5	23
78	Gene Xpert MTB/RIF assay confirms its value in the first multicentre, randomised, controlled trial conducted in primary-care settings in Africa. Pathogens and Global Health, 2014, 108, 127-127.	2.3	0
79	Evaluation of efficacy, pharmacokinetics and tolerability of peptidomimetic aspartic proteinase inhibitors as cream formulation in experimental vaginal candidiasis. Journal of Pharmacy and Pharmacology, 2014, 66, 1094-1101.	2.4	7
80	Detection of HLA-B*57:01 by real-time PCR: implementation into routine clinical practice and additional validation data. Pharmacogenomics, 2014, 15, 319-327.	1.3	17
81	Infection control and prevention measures to reduce the spread of vancomycin-resistant enterococci in hospitalized patients: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2014, 69, 1185-1192.	3.0	98
82	Predictive Models for Identification of Hospitalized Patients Harboring KPC-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2014, 58, 3514-3520.	3.2	75
83	Ophthalmic artery resistance index is increased in HIV-Infected patients and is influenced by protease inhibitors exposure. Journal of Infection, 2014, 68, 500-503.	3.3	1
84	Evaluation of emotion processing in HIV-infected patients and correlation with cognitive performance. BMC Psychology, 2013, 1, 3.	2.1	11
85	The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested caseâ€“control study. BMC Infectious Diseases, 2013, 13, 414.	2.9	51
86	Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 212 Td	3.0	45
87	Variability of Raltegravir Plasma Levels in the Clinical Setting. Pharmacology, 2013, 92, 43-48.	2.2	9
88	Mortality in patients with early- or late-onset candidaemia. Journal of Antimicrobial Chemotherapy, 2013, 68, 927-935.	3.0	37
89	Revised Central Nervous System Neuropenetration-Effectiveness Score is Associated with Cognitive Disorders in HIV-Infected Patients with Controlled Plasma Viraemia. Antiviral Therapy, 2013, 18, 153-160.	1.0	52
90	Predictors of Mortality in Bloodstream Infections Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Importance of Combination Therapy. Clinical Infectious Diseases, 2012, 55, 943-950.	5.8	855

#	Article	IF	Citations
91	High rate of Quantiferon positive and tuberculin negative tests in infants born at a large Italian University Hospital in 2011: a cautionary hypothesis. Pathogens and Global Health, 2012, 106, 8-11.	2.3	3
92	Candida and candidiasis in HIV-infected patients. Aids, 2012, 26, 1457-1472.	2.2	138
93	Is There a Drugâ€"Drug Interaction Between Darunavir/Ritonavir and Raltegravir?. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, e18-e20.	2.1	3
94	Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study. BMC Infectious Diseases, 2012, 12, 296.	2.9	73
95	Nosocomial acquisition of methicillin-resistant Staphyloccocus aureus (MRSA) and extended-spectrum beta-lactamase (ESBL) Enterobacteriaceae in hospitalised patients: a prospective multicenter study. BMC Infectious Diseases, 2012, 12, 74.	2.9	8
96	Effect of Aging and Human Immunodeficiency Virus Infection on Cognitive Abilities. Journal of the American Geriatrics Society, 2012, 60, 2048-2055.	2.6	30
97	Detecting risk and predicting patient mortality in patients with extended-spectrum Î²-lactamase-producing Enterobacteriaceae bloodstream infections. Future Microbiology, 2012, 7, 1173-1189.	2.0	55
98	Multidrug-Resistant Proteus mirabilis Bloodstream Infections: Risk Factors and Outcomes. Antimicrobial Agents and Chemotherapy, 2012, 56, 3224-3231.	3.2	51
99	Bicyclic peptidomimetics targeting secreted aspartic protease 2 (SAP2) from Candida albicans reveal a constrained inhibitory chemotype. Bioorganic and Medicinal Chemistry, 2012, 20, 7206-7213.	3.0	11
100	Increased ophthalmic artery resistance index is associated with cognitive impairment in HIV-infected patients. Journal of Infection, 2012, 65, 439-446.	3.3	16
101	Risk Factors and Outcomes of Candidemia Caused by Biofilm-Forming Isolates in a Tertiary Care Hospital. PLoS ONE, 2012, 7, e33705.	2.5	170
102	Management of serious meticillin-resistant Staphylococcus aureus infections: what are the limits?. International Journal of Antimicrobial Agents, 2011, 37, 202-209.	2.5	59
103	Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: Potential role for an unexpected drug interaction. Pharmacological Research, 2011, 63, 249-253.	7.1	23
104	Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients. Vaccine, 2011, 29, 2836-2839.	3.8	29
105	Prospective evaluation of epidemiological, clinical, and microbiological features of pandemic influenza A (H1N1) virus infection in Italy. Journal of Medical Virology, 2011, 83, 2057-2065.	5.0	11
106	Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients. Journal of Infection, 2011, 62, 319-321.	3.3	13
107	Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR. Pharmacogenomics, 2011, 12, 567-576.	1.3	35
108	The Effect of Polymorphisms in Candidate Genes on the Long-Term Risk of Lipodystrophy and Dyslipidemia in HIV-Infected White Patients Starting Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2011, 27, 1299-1309.	1.1	16

#	Article	IF	Citations
109	Treatment of Skin and Soft Tissue Infections Due to Community-Associated Methicillin-Resistant Staphylococcus aureus in Europe: The Role of Trimethoprim-sulfamethoxazole. Clinical Infectious Diseases, 2011, 52, 1471-1472.	5.8	14
110	Identifying Patients Harboring Extended-Spectrum-Î²-Lactamase-Producing Enterobacteriaceae on Hospital Admission: Derivation and Validation of a Scoring System. Antimicrobial Agents and Chemotherapy, 2011, 55, 3485-3490.	3.2	137
111	Lipid-lowering effect of tenofovir in HIV-infected patients. Journal of Antimicrobial Chemotherapy, 2011, 66, 682-683.	3.0	24
112	Prosthetic joint infection: Recent developments in diagnosis and management. Journal of Infection, 2010, 61, 443-448.	3.3	97
113	Comparison of expression vectors in Lactobacillus reuteriâ€ƒ strains. FEMS Microbiology Letters, 2010, 308, 8-15.	1.8	41
114	The Threshold Bootstrap Clustering: A New Approach to Find Families or Transmission Clusters within Molecular Quasispecies. PLoS ONE, 2010, 5, e13619.	2.5	15
115	HIV INFECTION, ANTIRETROVIRAL THERAPY AND CARDIOVASCULAR RISK. Mediterranean Journal of Hematology and Infectious Diseases, 2010, 2, e2010034.	1.3	15
116	Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy. Journal of Antimicrobial Chemotherapy, 2010, 65, 2050-2052.	3.0	33
117	Rate of CD4⁺Cell Count Increase over Periods of Viral Load Suppression: Relationship with the Number of Previous Virological Failures. Clinical Infectious Diseases, 2010, 51, 456-464.	5.8	21
118	Costs of Bloodstream Infections Caused by Escherichia coli and Influence of Extended-Spectrum-Î²-Lactamase Production and Inadequate Initial Antibiotic Therapy. Antimicrobial Agents and Chemotherapy, 2010, 54, 4085-4091.	3.2	185
119	Identification of Inhibitors of Drug-Resistant Candida albicans Strains from a Library of Bicyclic Peptidomimetic Compounds. Journal of Medicinal Chemistry, 2010, 53, 2502-2509.	6.4	29
120	Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice. Journal of Antimicrobial Chemotherapy, 2009, 64, 109-117.	3.0	71
121	Evaluation of the antiretroviral effects of a PEG-conjugated peptide derived from human CD38. Expert Opinion on Therapeutic Targets, 2009, 13, 141-152.	3.4	5
122	Virological Suppression Reduces Clinical Progression in Patients with Multiclass-Resistant HIV Type 1. AIDS Research and Human Retroviruses, 2009, 25, 261-267.	1.1	10
123	Antibiotic Usage and Risk of Colonization and Infection with Antibiotic-Resistant Bacteria: a Hospital Population-Based Study. Antimicrobial Agents and Chemotherapy, 2009, 53, 4264-4269.	3.2	127
124	Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance. Journal of Antimicrobial Chemotherapy, 2009, 64, 398-410.	3.0	6
125	Incidence and clinical impact of extended-spectrum-Î²-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. Journal of Infection, 2009, 58, 299-307.	3.3	144
126	Factors associated with mortality in bacteremic patients with hematologic malignancies. Diagnostic Microbiology and Infectious Disease, 2009, 64, 320-326.	1.8	82

#	Article	IF	Citations
127	Candidaemia in Patients with an Inserted Medical Device. Drugs, 2009, 69, 33-38.	10.9	43
128	Rapid screening tests for meticillin-resistant Staphylococcus aureus at hospital admission: systematic review and meta-analysis. Lancet Infectious Diseases, The, 2009, 9, 546-554.	9.1	108
129	Attitudes and practices of dentists treating patients infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Medical Science Monitor, 2009, 15, PH49-56.	1.1	6
130	Are mutations in HIV type-1 reverse transcriptase 245 codon predictive of abacavir hypersensitivity reaction?. Antiviral Therapy, 2009, 14, 99-101.	1.0	3
131	Bloodstream Infections Caused by Extended-Spectrum-Î²-Lactamase- Producing Escherichia coli : Risk Factors for Inadequate Initial Antimicrobial Therapy. Antimicrobial Agents and Chemotherapy, 2008, 52, 3244-3252.	3.2	104
132	Prediction models to identify hospitalized patients at risk of being colonized or infected with multidrug-resistant Acinetobacter baumannii calcoaceticus complex. Journal of Antimicrobial Chemotherapy, 2008, 62, 1130-1137.	3.0	48
133	Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome. Journal of Antimicrobial Chemotherapy, 2008, 62, 1379-1385.	3.0	50
134	Response of Feline Immunodeficiency Virus (FIV) to Tipranavir May Provide New Clues for Development of Broad-Based Inhibitors of Retroviral Proteases Acting on Drug-Resistant HIV-1. Current HIV Research, 2008, 6, 306-317.	0.5	12
135	Electronic Prescribing. , 2008, , 41-67.		0
136	Predictors of Mortality in Patients with Bloodstream Infections Caused by Extended-Spectrum-Î²-Lactamase-Producing Enterobacteriaceae : Importance of Inadequate Initial Antimicrobial Treatment. Antimicrobial Agents and Chemotherapy, 2007, 51, 1987-1994.	3.2	382
137	Prediction of specific pathogens in patients with sepsis: evaluation of TREAT, a computerized decision support system. Journal of Antimicrobial Chemotherapy, 2007, 59, 1204-1207.	3.0	29
138	Improved Interpretation of Genotypic Changes in the HIVâ€1 Reverse Transcriptase Coding Region That Determine the Virological Response to Didanosine. Journal of Infectious Diseases, 2007, 196, 1645-1653.	4.0	16
139	Association of HIV-1 Replication Capacity With Treatment Outcomes in Patients With Virologic Treatment Failure. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 45, 411-417.	2.1	13
140	Biofilm Production by Candida Species and Inadequate Antifungal Therapy as Predictors of Mortality for Patients with Candidemia. Journal of Clinical Microbiology, 2007, 45, 1843-1850.	3.9	300
141	Effects of Antiretroviral Therapy on Tube-Like Network Formation of Human Endothelial Cells. Biological and Pharmaceutical Bulletin, 2007, 30, 982-984.	1.4	3
142	Sphingosine 1-phosphate promotes antigen processing and presentation to CD4+ T cells in Mycobacterium tuberculosis-infected monocytes. Biochemical and Biophysical Research Communications, 2007, 361, 687-693.	2.1	11
143	Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. Diagnostic Microbiology and Infectious Disease, 2007, 58, 325-331.	1.8	104
144	Imatinib interferes with survival of multi drug resistant Kaposi's sarcoma cells. FEBS Letters, 2007, 581, 5897-5903.	2.8	35

#	Article	IF	Citations
145	On the use of chloroquine for chikungunya. Lancet Infectious Diseases, The, 2007, 7, 633.	9.1	18
146	Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2007, 61, 26-38.	3.0	340
147	Metallo-Î²-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues. International Journal of Antimicrobial Agents, 2007, 29, 380-388.	2.5	134
148	Risk scoring and bloodstream infections. International Journal of Antimicrobial Agents, 2007, 30, 88-92.	2.5	9
149	Characterization of JC virus in cerebrospinal fluid from HIV-1 infected patients with progressive multifocal leukoencephalopathy: insights into viral pathogenesis and disease prognosis. Journal of NeuroVirology, 2007, 13, 338-346.	2.1	23
150	Declining Prevalence of HIV-1 Drug Resistance in Treatment-Failing Patients: A Clinical Cohort Study. Antiviral Therapy, 2007, 12, 835-839.	1.0	29
151	Risks and benefits of chloroquine use in anticancer strategies. Lancet Oncology, The, 2006, 7, 792-793.	10.7	46
152	New insights into the antiviral effects of chloroquine. Lancet Infectious Diseases, The, 2006, 6, 67-69.	9.1	458
153	The Importance of Addressing Multidrug Resistance and Not Assuming Single-Drug Resistance in Case-Control Studies. Infection Control and Hospital Epidemiology, 2006, 27, 670-674.	1.8	17
154	Benefit of Appropriate Empirical Antibiotic Treatment: Thirty-day Mortality and Duration of Hospital Stay. American Journal of Medicine, 2006, 119, 970-976.	1.5	168
155	The Importance of Addressing Multidrug Resistance and Not Assuming Single-Drug Resistance in Case-Control Studies. Infection Control and Hospital Epidemiology, 2006, 27, 670-674.	1.8	15
156	Granulocyte colony-stimulating factor enhances the in vitro cytotoxicity of gemtuzumab ozogamicin against acute myeloid leukemia cell lines and primary blast cells. Experimental Hematology, 2006, 34, 54-65.	0.4	25
157	Quinoline antimalarials as investigational drugs for HIV-1/AIDS: in vitro effects on HIV-1 replication, HIV-1 response to antiretroviral drugs, and intracellular antiretroviral drug concentrations. Drug Development Research, 2006, 67, 806-817.	2.9	10
158	Improving empirical antibiotic treatment using TREAT, a computerized decision support system: cluster randomized trial. Journal of Antimicrobial Chemotherapy, 2006, 58, 1238-1245.	3.0	181
159	Bloodstream Infections Caused by Extended-Spectrum-Î²-Lactamase-Producing Klebsiella pneumoniae : Risk Factors, Molecular Epidemiology, and Clinical Outcome. Antimicrobial Agents and Chemotherapy, 2006, 50, 498-504.	3.2	243
160	Evaluation of the New VITEK 2 Extended-Spectrum Beta-Lactamase (ESBL) Test for Rapid Detection of ESBL Production in Enterobacteriaceae Isolates. Journal of Clinical Microbiology, 2006, 44, 3257-3262.	3.9	57
161	Three-Year Clinical Outcomes of Resistance Genotyping and Expert Advice: Extended follow-up of the Argenta Trial. Antiviral Therapy, 2006, 11, 321-327.	1.0	11
162	Lopinavir/Ritonavir or Efavirenz plus two Nucleoside Analogues as First-Line Antiretroviral Therapy: A Non-Randomized Comparison. Antiviral Therapy, 2006, 11, 609-618.	1.0	19

#	Article	IF	Citations
163	Role of Lymphocyte Multidrug Resistance Protein 1 in HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 257-266.	2.1	16
164	Macrophage chemoattractant protein-1 levels in cerebrospinal fluid correlate with containment of JC virus and prognosis of acquired immunodeficiency syndromeâ€“associated progressive multifocal leukoencephalopathy. Journal of NeuroVirology, 2005, 11, 219-224.	2.1	20
165	Dental care and HIV-infected individuals: are they equally treated?. Community Dentistry and Oral Epidemiology, 2005, 33, 447-453.	1.9	14
166	Reduced Rate of Diagnostic Positive Detection of JC Virus DNA in Cerebrospinal Fluid in Cases of Suspected Progressive Multifocal Leukoencephalopathy in the Era of Potent Antiretroviral Therapy. Journal of Clinical Microbiology, 2005, 43, 4175-4177.	3.9	118
167	Economic evaluation of HIV treatments: The I.CO.N.A. cohort study. Health Policy, 2005, 74, 304-313.	3.0	13
168	Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop. AIDS Reviews, 2005, 7, 161-7.	1.0	3
169	HIV Protease Inhibitors Prevent Mitochondrial Hyperpolarization and Redox Imbalance and Decrease Endogenous Uncoupler Protein-2 Expression in Gp120-Activated Human T Lymphocytes. Antiviral Therapy, 2005, 10, 29-45.	1.0	10
170	ESBL-producing multidrug-resistant Providencia stuartii infections in a university hospital. Journal of Antimicrobial Chemotherapy, 2004, 53, 277-282.	3.0	68
171	Hemangiomas and Other Congenital Malformations in Infants Exposed to Antiretroviral Therapy In Utero. JAMA - Journal of the American Medical Association, 2004, 291, 305-305.	7.4	12
172	Anti-HIV Effects of Chloroquine. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 223-232.	2.1	104
173	Anti-retroviral therapy with protease inhibitors decreases virulence enzyme expression in vivo byCandida albicanswithout selection of avirulent fungus strains or decreasing their anti-mycotic susceptibility. FEMS Immunology and Medical Microbiology, 2004, 41, 27-34.	2.7	33
174	Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving Highly Active Anti Retroviral Therapy. BMC Infectious Diseases, 2004, 4, 46.	2.9	65
175	HIV infection, HAART, and endothelial adhesion molecules: current perspectives. Lancet Infectious Diseases, The, 2004, 4, 213-222.	9.1	133
176	Deep Salvage With Amprenavir and Lopinavir/Ritonavir. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 359-366.	2.1	33
177	Effects of chloroquine on viral infections: an old drug against today's diseases. Lancet Infectious Diseases, The, 2003, 3, 722-727.	9.1	1,022
178	Interpretation systems for genotypic drug resistance of HIV-1. Scandinavian Journal of Infectious Diseases, 2003, 35, 29-34.	1.5	11
179	Mitochondrial Membrane Hyperpolarization Hijacks Activated T Lymphocytes Toward the Apoptotic-Prone Phenotype: Homeostatic Mechanisms of HIV Protease Inhibitors. Journal of Immunology, 2003, 170, 6006-6015.	0.8	74
180	Older HIV-positive patients in the era of highly active antiretroviral therapy. Aids, 2003, 17, 128-131.	2.2	55

#	Article	IF	Citations
181	Increased soluble markers of endothelial dysfunction in HIV-positive patients under highly active antiretroviral therapy. Aids, 2003, 17, 765-768.	2.2	54
182	Antiretroviral Therapy with Protease Inhibitors Has an Early, Immune Reconstitutionâ€“Independent Beneficial Effect onCandidaVirulence and Oral Candidiasis in Human Immunodeficiency Virusâ€“Infected Subjects. Journal of Infectious Diseases, 2002, 185, 188-195.	4.0	79
183	Azole Susceptibility Patterns and Genetic Relationship Among Oral Candida Strains Isolated in the Era of Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 31, 38-44.	2.1	17
184	In Vitro and In Vivo Modulation of MDR1/P-Glycoprotein in HIV-Infected Patients Administered Highly Active Antiretroviral Therapy and Liposomal Doxorubicin. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 30, 369-378.	2.1	20
185	Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). Aids, 2002, 16, 369-379.	2.2	189
186	Risk factors and predictors of mortality of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in HIV-infected patients. Journal of Antimicrobial Chemotherapy, 2002, 50, 375-382.	3.0	66
187	Antiapoptotic Activity by HIV Protease Inhibitors either Alone or Boostered. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 31, 545-546.	2.1	2
188	HIV proteinase inhibitors: do they really work against Candida in a clinical setting?. Trends in Microbiology, 2002, 10, 177-178.	7.7	17
189	Multidrug-Resistant Pseudomonas Aeruginosa Bloodstream Infections: Analysis of Trends in Prevalence and Epidemiology. Emerging Infectious Diseases, 2002, 8, 220-221.	4.3	75
190	Differential induction of P-glycoprotein and MRP by rifamycins in T lymphocytes from HIV-1/tuberculosis co-infected patients. Aids, 2002, 16, 1563-1565.	2.2	6
191	Recurrent venous thrombosis in a patient with haemophilia A and HIV infection. Haematologica, 2002, 87, ECR04.	3.5	4
192	Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. Aids, 2001, 15, 1483-1491.	2.2	175
193	HIV-Protease Inhibitors Contribute to P-Glycoprotein Efflux Function Defect in Peripheral Blood Lymphocytes From HIV-Positive Patients Receiving HAART. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 27, 321-330.	2.1	25
194	HIV-Protease Inhibitors Contribute to P-Glycoprotein Efflux Function Defect in Peripheral Blood Lymphocytes From HIV-Positive Patients Receiving HAART. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 27, 321-330.	2.1	33
195	Potent anti-retroviral therapy with or without cidofovir for AIDS-associated progressive multifocal leukoencephalopathy: Extended follow-up of an observational study. Journal of NeuroVirology, 2001, 7, 364-368.	2.1	64
196	Glycopeptide Resistance among Coagulaseâ€Negative Staphylococci that Cause Bacteremia: Epidemiological and Clinical Findings from a Caseâ€Control Study. Clinical Infectious Diseases, 2001, 33, 1628-1635.	5.8	48
197	Decreased function of Fas in patients displaying delayed progression of HIV-induced immune deficiency. The Hematology Journal, 2001, 2, 220-227.	1.4	7
198	HIV-Associated Bacteremia: How It Has Changed in the Highly Active Antiretroviral Therapy (HAART) Era. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 23, 145-151.	2.1	15

#	Article	IF	Citations
199	Expression of the Novel T Cell Activation Molecule hpH4 in HIV-Infected Patients: Correlation with Disease Status. AIDS Research and Human Retroviruses, 2000, 16, 549-557.	1.1	8
200	HIV-Associated Bacteremia: How It Has Changed in the Highly Active Antiretroviral Therapy (HAART) Era. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 23, 145-151.	2.1	54
201	Highly active antiretroviral therapy decreases the incidence of visceral leishmaniasis in HIV-infected individuals. Aids, 2000, 14, 2948-2949.	2.2	20
202	Role of Protease Inhibitors in Preventing Recurrent Oral Candidosis in Patients With HIV Infection: A Prospective Case-Control Study. Journal of Acquired Immune Deficiency Syndromes (1999), 1999, 21, 20-25.	2.1	126
203	Characterization of a novel human surface molecule selectively expressed by mature thymocytes, activated T cells and subsets of T cell lymphomas. European Journal of Immunology, 1999, 29, 2863-2874.	2.9	23
204	In Vitro and In Vivo Anticandidal Activity of Human Immunodeficiency Virus Protease Inhibitors. Journal of Infectious Diseases, 1999, 180, 448-453.	4.0	205
205	A new, striking morphological alteration of P-glycoprotein expression in NK cells from AIDS patients. Immunology Letters, 1998, 60, 19-21.	2.5	10
206	Flow cytometric detection of perforin in normal human lymphocyte subpopulations defined by expression of activation/differentiation antigens. Immunology Letters, 1998, 60, 51-55.	2.5	26
207	Highly Active Antiretroviral Therapy Decreases the Incidence of Bacteremia in Human Immunodeficiency Virusâ€Infected Individuals. Clinical Infectious Diseases, 1998, 27, 901-902.	5.8	21
208	The Role of Oxidative Imbalance in Progression to AIDS: Effect of the Thiol SupplierN-Acetylcysteine. AIDS Research and Human Retroviruses, 1998, 14, 1589-1596.	1.1	45
209	Nosocomial Bloodstream Infections in HIV-Infected Patients: Attributable Mortality and Extension of Hospital Stay. Journal of Acquired Immune Deficiency Syndromes, 1998, 19, 490-497.	0.3	32
210	Gastric cryptosporidiosis complicating HIV infection: case report and review of the literature. European Journal of Gastroenterology and Hepatology, 1997, 9, 307-310.	1.6	26
211	Osteoarticular bacterial infections are rare in HIV-infected patients: 14 cases found among 4, 023 HIV-infected patients. Acta Orthopaedica, 1997, 68, 554-558.	1.4	35
212	Age as a prognostic factor in AIDS. Lancet, The, 1996, 348, 623-624.	13.7	9
213	Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection. Journal of Antimicrobial Chemotherapy, 1996, 38, 691-699.	3.0	55
214	Evidence of a selective depletion of a CD16⁺ CD56⁺ CD8⁺ natural killer cell subset during HIV infection. Cytometry, 1995, 22, 10-15.	1.8	62
215	P-170 glycoprotein (P-170) is involved in the impairment of natural killer cell-mediated cytotoxicity in HIV+ patients. Immunology Letters, 1995, 47, 223-226.	2.5	7
216	Synthetic Peptides Corresponding to Sequences in HIV Envelope gp41 and gp120 EnhanceIn VitroProduction of Interleukin-1 and Tumor Necrosis Factor but Depress Production of Interferon-Î±, Interferon-Î³ and Interleukin-2. Viral Immunology, 1991, 4, 33-42.	1.3	41

#	Article	IF	Citations
217	Role of Polymorphonuclear Leukocytes in Infection by Retroviruses with Emphasis on the Human Immunodeficiency Virus. Viral Immunology, 1990, 3, 173-194.	1.3	20
218	Inhibition of normal human natural killer cell activity by human immunodeficiency virus synthetic transmembrane peptides. Cellular Immunology, 1988, 115, 57-65.	3.0	52
219	Patients with condyloma acuminatum exhibit decreased interleukin-2 and interferon gamma production and depressed natural killer activity. Journal of Clinical Immunology, 1987, 7, 304-311.	3.8	49
220	Sonographic Patterns of the Gallbladder in Acute Viral Hepatitis. Journal of Clinical Ultrasound, 1984, 12, 141-146.	0.8	23